AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7729019 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical group (CABG surgery)
Number of subjects: 912
Study 7729019 — intervention group
Group type: COMPARATOR
Intervention: Medical group (nonsurgical therapy)
Number of subjects: 912
Study 7729019 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized trial participants (CABG surgery)
Number of subjects: 912
Study 7729019 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomizable patients (CABG surgery)
Number of subjects: 912
Study 2045533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprostene (120 ng/kg/min in 8-hour daily infusions for 7 days)
Number of subjects: 211
Study 2045533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 2045533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprostene
Number of subjects: 211
Study 2045533 — intervention group
Group type: COMPARATOR
Intervention: Ciprostene and Placebo
Number of subjects: 211
Study 7426351 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza virus RIT 4050 (H3N2) vaccine
Number of subjects: 0
Study 31135498 — intervention group
Group type: EXPERIMENTAL
Intervention: Best performing icon alarms
Number of subjects: 123
Study 31135498 — intervention group
Group type: COMPARATOR
Intervention: Worst performing icon alarms
Number of subjects: 123
Study 28705786 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic treatment (Lactobacillus casei, L. rhamnosus, L. plantarum, Bifidobacterium lactis, and prebiotics)
Number of subjects: 146
Study 28705786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 25810595 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocrystalline hydroxyapatite (NcHA)
Number of subjects: 20
Study 25810595 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocrystalline hydroxyapatite (NcHA) with platelet-rich fibrin (PRF)
Number of subjects: 20
Study 23461638 — intervention group
Group type: EXPERIMENTAL
Intervention: GA + TEA (General Anesthesia + Thoracic Epidural Anesthesia)
Number of subjects: 40
Study 23461638 — intervention group
Group type: COMPARATOR
Intervention: GA (General Anesthesia)
Number of subjects: 40
Study 21563871 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk supplemented with 5 ppm fluoride and probiotic bacteria (Lactobacillus rhamnosus LB21, 10^7 CFU/mL)
Number of subjects: 160
Study 21563871 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk with only probiotic bacteria
Number of subjects: 160
Study 21563871 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk containing only fluoride
Number of subjects: 160
Study 21563871 — intervention group
Group type: COMPARATOR
Intervention: Standard milk (placebo)
Number of subjects: 160
Study 19731357 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner-assisted emotional disclosure
Number of subjects: 130
Study 19731357 — intervention group
Group type: COMPARATOR
Intervention: Couples cancer education/support intervention
Number of subjects: 130
Study 17876280 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine combined with HBIg
Number of subjects: 29
Study 17876280 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine alone
Number of subjects: 29
Study 17876280 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HBIg + Lamivudine and Lamivudine alone)
Number of subjects: 29
Study 17876280 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients adhering to long-term prophylaxis with lamivudine after early withdrawal of HBIg
Number of subjects: 29
Study 15234485 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Flex foot
Number of subjects: 11
Study 15234485 — intervention group
Group type: COMPARATOR
Intervention: Conventional SAFE foot
Number of subjects: 11
Study 11731649 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (5 mg as sulfate)
Number of subjects: 1154
Study 11731649 — intervention group
Group type: COMPARATOR
Intervention: Calcium, phosphorus, folate, and iron supplementation
Number of subjects: 1154
Study 9205759 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebrotidine 150 mg b.i.d
Number of subjects: 8
Study 9205759 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebrotidine 300 mg b.i.d
Number of subjects: 8
Study 9205759 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebrotidine 500 mg b.i.d
Number of subjects: 8
Study 7991739 — intervention group
Group type: EXPERIMENTAL
Intervention: Family interventions
Number of subjects: 350
Study 7991739 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 350
Study 3068401 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 102
Study 3068401 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosine
Number of subjects: 102
Study 3068401 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 102
Study 31862830 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and adjuvant middle meningeal artery embolization (ST+MMAE group)
Number of subjects: 46
Study 31862830 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment alone (ST group)
Number of subjects: 46
Study 29526457 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (200mg per day)
Number of subjects: 55
Study 29526457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 27129176 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide plus CHOP (T-CHOP)
Number of subjects: 65
Study 27129176 — intervention group
Group type: COMPARATOR
Intervention: CHOP alone
Number of subjects: 65
Study 27129176 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide plus CHOP (T-CHOP) in Bcl-2 positive and Bcl-6 negative patients
Number of subjects: 65
Study 27129176 — intervention group
Group type: COMPARATOR
Intervention: CHOP alone in Bcl-2 positive and Bcl-6 negative patients
Number of subjects: 65
Study 25706883 — intervention group
Group type: EXPERIMENTAL
Intervention: Zegerid (20 mg)
Number of subjects: 239
Study 25706883 — intervention group
Group type: COMPARATOR
Intervention: Losec (20 mg)
Number of subjects: 239
Study 24081841 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture length to wound length ratio (SL:WL) of more than 4 with small tissue bites and short stitch intervals at Sundsvall Hospital (SH)
Number of subjects: 36
Study 24081841 — intervention group
Group type: COMPARATOR
Intervention: Suture length to wound length ratio (SL:WL) of more than 4 with small tissue bites and short stitch intervals at Erasmus University Medical Center (EMC)
Number of subjects: 36
Study 24081841 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure time at Sundsvall Hospital (SH)
Number of subjects: 36
Study 24081841 — intervention group
Group type: COMPARATOR
Intervention: Closure time at Erasmus University Medical Center (EMC)
Number of subjects: 36
Study 20516439 — intervention group
Group type: EXPERIMENTAL
Intervention: MP-T (melphalan plus prednisone plus thalidomide 200 mg/d)
Number of subjects: 333
Study 20516439 — intervention group
Group type: COMPARATOR
Intervention: MP (melphalan plus prednisone)
Number of subjects: 333
Study 17923862 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower glycaemic index diet (GI 52)
Number of subjects: 19
Study 17923862 — intervention group
Group type: COMPARATOR
Intervention: Higher glycaemic index diet (GI 64)
Number of subjects: 19
Study 17923862 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory investigation days (after lower and higher GI test breakfasts)
Number of subjects: 19
Study 16614052 — intervention group
Group type: EXPERIMENTAL
Intervention: Musically enhanced bird song stimulus (2-h presentation from 0600 to 0800)
Number of subjects: 11
Study 16614052 — intervention group
Group type: COMPARATOR
Intervention: Control stimulus (2-h presentation from 0600 to 0800)
Number of subjects: 11
Study 12815566 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent telephone follow-up intervention by trained nurses
Number of subjects: 1518
Study 12815566 — intervention group
Group type: COMPARATOR
Intervention: Usual follow-up (Control)
Number of subjects: 1518
Study 10606935 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (n = 6)
Number of subjects: 12
Study 10606935 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 12
Study 8872060 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) 600 micrograms sublingually
Number of subjects: 12
Study 1501967 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-ear stimulus input
Number of subjects: 12
Study 1501967 — intervention group
Group type: EXPERIMENTAL
Intervention: /Pa/-syllable presentations
Number of subjects: 12
Study 1501967 — intervention group
Group type: EXPERIMENTAL
Intervention: /Ba/-syllable presentations
Number of subjects: 12
Study 1501967 — intervention group
Group type: EXPERIMENTAL
Intervention: /Pa/-syllable presented to the left ear
Number of subjects: 12
Study 1501967 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG recorded from F3, Fz, and F4
Number of subjects: 12
Study 1501967 — intervention group
Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 12
Study 6432417 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin 6 mg/day
Number of subjects: 46
Study 6432417 — intervention group
Group type: COMPARATOR
Intervention: D-penicillamine 500 mg/day
Number of subjects: 46
Study 31107311 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 0
Study 31107311 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 0
Study 27143319 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN) plus optimal medical therapy
Number of subjects: 60
Study 27143319 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (control group)
Number of subjects: 60
Study 25525065 — intervention group
Group type: EXPERIMENTAL
Intervention: Greek traditional dancing programme (Group A)
Number of subjects: 31
Study 25525065 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group (Group B)
Number of subjects: 31
Study 23726630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine mycophenolate mofetil (CM)
Number of subjects: 105
Study 23726630 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus/mycophenolate mofetil (TM)
Number of subjects: 105
Study 23726630 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus/mycophenolate mofetil with conversion to everolimus (TErl)
Number of subjects: 105
Study 23726630 — intervention group
Group type: EXPERIMENTAL
Intervention: Not randomized (NR)
Number of subjects: 105
Study 23726630 — intervention group
Group type: EXPERIMENTAL
Intervention: BK viremia
Number of subjects: 105
Study 23726630 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PAN
Number of subjects: 105
Study 21362715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention condition (adding or removing air to maintain cuff pressure)
Number of subjects: 32
Study 21362715 — intervention group
Group type: COMPARATOR
Intervention: Control condition (usual care)
Number of subjects: 32
Study 21362715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention condition (adding air to cuff)
Number of subjects: 32
Study 19683087 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted H5N1 vaccine
Number of subjects: 1206
Study 17302879 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 50-mg
Number of subjects: 10
Study 17302879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 14759617 — intervention group
Group type: EXPERIMENTAL
Intervention: NuvaRing with a single dose of antimycotic
Number of subjects: 26
Study 14759617 — intervention group
Group type: EXPERIMENTAL
Intervention: NuvaRing with multiple doses of antimycotic vaginal suppository
Number of subjects: 26
Study 14759617 — intervention group
Group type: COMPARATOR
Intervention: NuvaRing with antimycotic vaginal cream
Number of subjects: 26
Study 14759617 — intervention group
Group type: COMPARATOR
Intervention: NuvaRing alone
Number of subjects: 26
Study 11802289 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg
Number of subjects: 176
Study 11802289 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine 10 mg
Number of subjects: 176
Study 9778666 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 18
Study 9778666 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 18
Study 7881139 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 416
Study 7881139 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine gluconate scrub
Number of subjects: 416
Study 3130256 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (VPA) 500 mg t.i.d. for 5 days
Number of subjects: 8
Study 3130256 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (VPA) in epileptic patients on established monotherapy
Number of subjects: 8
Study 3130256 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched controls)
Number of subjects: 8
Study 30948271 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined alcohol and sex exposure
Number of subjects: 338
Study 30948271 — intervention group
Group type: COMPARATOR
Intervention: Sex only exposure
Number of subjects: 338
Study 30948271 — intervention group
Group type: COMPARATOR
Intervention: Alcohol only exposure
Number of subjects: 338
Study 30948271 — intervention group
Group type: COMPARATOR
Intervention: No risk exposure
Number of subjects: 338
Study 28342967 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids and vitamin E co-supplementation (1000 mg omega-3 from flaxseed oil plus 400 IU vitamin E)
Number of subjects: 60
Study 28342967 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids and vitamin E co-supplementation
Number of subjects: 60
Study 26556955 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine and ropivacaine
Number of subjects: 36
Study 26556955 — intervention group
Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 36
Study 23237175 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (training of opinion leaders to disseminate stigma reduction messages)
Number of subjects: 1760
Study 21218039 — intervention group
Group type: EXPERIMENTAL
Intervention: Type D individuals
Number of subjects: 1357
Study 21218039 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean DS14
Number of subjects: 1357
Study 21218039 — intervention group
Group type: EXPERIMENTAL
Intervention: General population and cardiovascular patients with Type D personality
Number of subjects: 1357
Study 18716734 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient food supplement (MMFS)
Number of subjects: 123
Study 18716734 — intervention group
Group type: COMPARATOR
Intervention: Control group (day scholars who did not eat at the school)
Number of subjects: 123
Study 17140526 — intervention group
Group type: EXPERIMENTAL
Intervention: Vector system (piezo-driven ultrasonic device)
Number of subjects: 31
Study 17140526 — intervention group
Group type: COMPARATOR
Intervention: Conventional method (dental bur)
Number of subjects: 31
Study 17140526 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 31
Study 12816748 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (6 sessions/week at 70-80% of maximum heart rate for 30-60 min/session)
Number of subjects: 39
Study 12816748 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 39
Study 14635300 — intervention group
Group type: EXPERIMENTAL
Intervention: Mensendieck system (MS)
Number of subjects: 20
Study 14635300 — intervention group
Group type: EXPERIMENTAL
Intervention: Body awareness therapy (BAT)
Number of subjects: 20
Study 9349677 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic Auditory Stimulation (RAS) during gait training
Number of subjects: 10
Study 9349677 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy gait program (Control)
Number of subjects: 10
Study 8211671 — intervention group
Group type: EXPERIMENTAL
Intervention: External irradiation with a dose per fraction of 2 Gy
Number of subjects: 203
Study 8211671 — intervention group
Group type: EXPERIMENTAL
Intervention: External irradiation with a dose per fraction of 3 Gy
Number of subjects: 203
Study 8211671 — intervention group
Group type: EXPERIMENTAL
Intervention: External irradiation with a dose per fraction of 4 Gy
Number of subjects: 203
Study 8211671 — intervention group
Group type: EXPERIMENTAL
Intervention: External irradiation with a dose per fraction of 5.4 Gy
Number of subjects: 203
Study 2869723 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dezocine
Number of subjects: 160
Study 2869723 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg dezocine
Number of subjects: 160
Study 2869723 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg butorphanol
Number of subjects: 160
Study 2869723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 29856817 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin, 5000 IU daily
Number of subjects: 708
Study 29856817 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH), 5000 IU twice daily
Number of subjects: 708
Study 26947602 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg once a day
Number of subjects: 423
Study 26947602 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20mg on demand
Number of subjects: 423
Study 26947602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study 26947602 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic surgery (yes)
Number of subjects: 423
Study 26947602 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic surgery (no)
Number of subjects: 423
Study 26947602 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of nerve sparing (NSS <2.5)
Number of subjects: 423
Study 26947602 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of nerve sparing (NSS ≥2.5)
Number of subjects: 423
Study 26947602 — intervention group
Group type: EXPERIMENTAL
Intervention: High presurgery sexual desire (IIEF item 12: ≥3.5)
Number of subjects: 423
Study 26947602 — intervention group
Group type: EXPERIMENTAL
Intervention: Low presurgery sexual desire (IIEF item 12: <3.5)
Number of subjects: 423
Study 26947602 — intervention group
Group type: EXPERIMENTAL
Intervention: High confidence to get and maintain an erection (IIEF item 15: ≥3.5)
Number of subjects: 423
Study 26947602 — intervention group
Group type: EXPERIMENTAL
Intervention: Low confidence to get and maintain an erection (IIEF item 15: <3.5)
Number of subjects: 423
Study 24231654 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 8.75 mg lozenge
Number of subjects: 204
Study 24231654 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 204
Study 23257488 — intervention group
Group type: EXPERIMENTAL
Intervention: Submerged healing
Number of subjects: 48
Study 23257488 — intervention group
Group type: COMPARATOR
Intervention: Non-submerged healing
Number of subjects: 48
Study 20629630 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein aglycone
Number of subjects: 0
Study 20629630 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study 18727753 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-support groups
Number of subjects: 660
Study 18727753 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 660
Study 15688086 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg ghrelin (i.v. bolus injection)
Number of subjects: 9
Study 15688086 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 9
Study 12441831 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil and ketamine infusions targeting plasma concentrations of 75 ng/ml for alfentanil and 150 ng/ml for ketamine
Number of subjects: 0
Study 12441831 — intervention group
Group type: COMPARATOR
Intervention: Placebo equivalent
Number of subjects: 0
Study 10028212 — intervention group
Group type: EXPERIMENTAL
Intervention: Child psychotherapy
Number of subjects: 0
Study 10028212 — intervention group
Group type: COMPARATOR
Intervention: Academic tutoring (Control)
Number of subjects: 0
Study 7750916 — intervention group
Group type: EXPERIMENTAL
Intervention: GH at a dose of 0.5 IU/kg/week
Number of subjects: 63
Study 7750916 — intervention group
Group type: EXPERIMENTAL
Intervention: GH at a dose of 1.0 IU/kg/week
Number of subjects: 63
Study 2324409 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (400 micrograms)
Number of subjects: 20
Study 2324409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 40840 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 60
Study 40840 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 60
Study 31675621 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 50-200 mg/day
Number of subjects: 1402
Study 31675621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1402
Study 27739182 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue donepezil for 52 weeks
Number of subjects: 295
Study 27739182 — intervention group
Group type: EXPERIMENTAL
Intervention: Start memantine
Number of subjects: 295
Study 27739182 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil-memantine combined
Number of subjects: 295
Study 27739182 — intervention group
Group type: COMPARATOR
Intervention: Discontinue donepezil
Number of subjects: 295
Study 25530454 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink (3 mg of caffeine per kg of body mass)
Number of subjects: 16
Study 23895631 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei ssp paracasei F19 (LF19) 10^8 CFU
Number of subjects: 171
Study 23895631 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cereals without LF19)
Number of subjects: 171
Study 21836149 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 3276
Study 21836149 — intervention group
Group type: COMPARATOR
Intervention: Control (no cinacalcet)
Number of subjects: 3276
Study 19153263 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 150
Study 19153263 — intervention group
Group type: COMPARATOR
Intervention: Control (physician visits)
Number of subjects: 150
Study 16990605 — intervention group
Group type: EXPERIMENTAL
Intervention: FEIBA (factor VIII inhibitor‐bypassing activity)
Number of subjects: 48